Carlos L. Arteaga, MD

Carlos L. Arteaga, MD, director of the Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, discusses the use of capecitabine after neoadjuvant chemotherapy in patients with triple-negative breast cancer (TNBC).

In the phase III GEICAM/CIBOMA trial, there was not an improvement found in progression-free survival (PFS) in the experimental arm as compared to those randomized to observation. A subgroup analysis in this study showed there was improvement in PFS in patients with nonbasal TNBC, says Arteaga.

Videos

Carlos L. Arteaga, MD, discusses the use of capecitabine after neoadjuvant chemotherapy in patients with triple-negative breast cancer.

Comparing Data for Capecitabine After Neoadjuvant Chemotherapy in TNBC

Carlos L. Arteaga, MD, professor of medicine and cancer biology, Vanderbilt-Ingram Cancer Center, discusses the results and impact of the four-year follow-up analysis of the NeoALTTO trial, which analyzed patients with HER2-positive breast cancer.

The NeoALTTO trial set out to determine whether the higher pathologic complete response (pCR) rate achieved with lapatinib plus trastuzumab translated into better overall survival or event-free survival

The hazard for event-free survival was 65%-70% lower for patients who achieved pCR than for those who did not

This trial is important because the FDA now allows for the approval of novel therapies following testing in the adjuvant setting

Carlos L. Arteaga, MD, discusses the results and impact of the four-year follow-up analysis of the NeoALTTO trial, which analyzed patients with HER2-positive breast cancer.

Carlos L. Arteaga, MD | Authors

Articles

Comparing Data for Capecitabine After Neoadjuvant Chemotherapy in TNBC

Results and Impact of the Follow-Up of the NeoALTTO Trial